The Zacks Analyst Blog Highlights: AeroVironment, BioSpecifics, Codexis, Avid and American Outdoor
There are still winners on the index across industries that are easily surviving the worst start to September and have a solid Zacks Rank #1 (Strong Buy) or 2 (Buy).
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Codexis, Inc. (NASDAQ:CDXS),...
W.W. Grainger (GWW) will gain from its investment in e-commerce and digital capabilities as well as executing supply chain management actions and efforts to strengthen relationships with customers.
Codexis (CDXS) delivered earnings and revenue surprises of 83.33% and 14.09%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Wednesday reported a loss of $3.7 million in its second quarter.
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Codexis, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30:00 PM Eastern Time.
Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report second quarter 2018 financial results after market close on Wednesday, August 8, 2018. Codexis management...
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the appointment of Hicham Alaoui, Ph.D. to the newly created position of Vice President, Biotherapeutics Research & Development....
Stock Research Monitor: CLSD, CDXS, and CHRS
Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that it has dosed the first subjects in a first-in-human Phase 1a dose-escalation trial with CDX-6114, its orally administered...
Cimpress' (CMPR) management has decentralized operations to improve accountability for customer satisfaction and capital returns, simplify decision-making and improve the speed of execution.
Sonoco's (SON) prospects remain bright on the back of solid earnings estimate revision activity as well as an upbeat guidance.
REDWOOD CITY, Calif. (AP) _ Codexis Inc. (CDXS) on Thursday reported a loss of $4.7 million in its first quarter.
Total revenues increase 76% to $14.0 million on sharply higher R&D revenue
Codexis, Inc. (NASDAQ: CDXS) and Porton Pharma Solutions, Ltd. (SZSE: 300363) announce a strategic collaboration to deploy Codexis' world-leading biocatalyst technology within...
EnzymeWorks has been ordered by the United States District Court for the Northern District of California to retract its prior statements and press releases pertaining in any way to the settlement...
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Alliance Resource Partners,...
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced the pricing of an underwritten public offering of 3,750,000 shares of its common stock at a public offering price of...
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in...
